Why is Sanofi cutting 229 Blueprint Medicines jobs in Cambridge?

Sanofi is eliminating 229 Blueprint Medicines roles in Massachusetts, closing two legacy Cambridge sites, and moving remaining staff to its Cambridge Crossing campus. The company frames it as post-acquisition integration after its $9.1 billion Blueprint deal, but investors may see it as an early sign of broader portfolio and cost discipline under CEO Belén Garijo.